‘Antipsychotics Increase Mortality in Elderly Patients with Dementia’ <http://www.npc.nhs.uk/merec/cns/dementia/merec_extra_no39.php>
‘Aricept Tablets - Summary of Product Characteristics (SPC) - (eMC)’ <http://www.medicines.org.uk/emc/medicine/577/SPC/Aricept>
Bhasin M and others, ‘Cholinesterase Inhibitors in Dementia with Lewy Bodies—a Comparative Analysis’ (2007) 22 International Journal of Geriatric Psychiatry 890
‘British National Formulary’ <http://www.bnf.org/bnf/index.htm>
‘Centre for Medicines Optimisation - MTRAC | Independent Medicines Review | Midlands Therapeutics Review & Advisory Committee | Centre for Medicines Optimisation | Keele University’ <http://centreformedicinesoptimisation.co.uk/mtrac/>
‘Chronic Obstructive Pulmonary Disease’ <http://cks.nice.org.uk/chronic-obstructive-pulmonary-disease>
‘Clinical Guidelines, CG42 - Issued: November 2006’ <http://guidance.nice.org.uk/CG42>
‘Coeliac Disease: Recognition, Assessment and Management | Guidance and Guidelines | NICE’ <https://www.nice.org.uk/guidance/ng20>
‘Commissioners and Healthcare Professionals - Training Videos’ <http://healthcheck.nhs.uk/commissioners_and_providers/training/training_videos1/>
‘Complete Guide to Behavioural and Psychological Symptoms of Dementia’ <http://www.ipa-online.org/>
‘CPPE - Centre for Pharmacy Postgraduate Education’ <https://www.cppe.ac.uk/>
‘DH Living Well with Dementia: A National Dementia Strategy’ <https://www.gov.uk/government/organisations/department-of-health>
‘Ebixa 5mg/Pump Actuation Oral Solution, 20mg and 10 Mg Tablets and Treatment Initiation Pack - Summary of Product Characteristics (SPC) - (eMC)’ <http://www.medicines.org.uk/EMC/medicine/10175/SPC/rEbxia+5mg+pump+oral+solution%252c+20mg+and+10+mg+tablets+and+Treatment+Initiation+Pack/>
‘Electronic Medicines Compendium (eMC)’ <http://www.medicines.org.uk/emc/>
‘——’ <http://www.medicines.org.uk/emc/>
‘——’ <https://www.medicines.org.uk/emc/>
‘Evidence Search - Search Engine for Evidence in Health and Social Care’ <https://www.evidence.nhs.uk/>
‘——’ <https://www.evidence.nhs.uk/>
‘——’ <https://www.evidence.nhs.uk/>
‘Exelon - Summary of Product Characteristics (SPC) - (eMC)’ <https://www.medicines.org.uk/emc/search?q=Exelon+>
‘GOV.UK’ <https://www.gov.uk/government/organisations/department-of-health>
Greene RJ and Harris ND, Pathology and Therapeutics for Pharmacists: A Basis for Clinical Pharmacy Practice (3rd ed, Pharmaceutical Press 2008)
‘Heart Failure - Chronic’ <http://cks.nice.org.uk/heart-failure-chronic>
Hubley J, Copeman J and Woodall J, Practical Health Promotion (2nd ed, Polity Press 2013)
Kavirajan H and Schneider LS, ‘Efficacy and Adverse Effects of Cholinesterase Inhibitors and Memantine in Vascular Dementia: A Meta-Analysis of Randomised Controlled Trials’ (2007) 6 The Lancet Neurology 782
Kumar PJ and Clark ML, Kumar & Clark’s Clinical Medicine (8th ed, Saunders Elsevier 2012) <https://www.dawsonera.com/abstract/9780702053047>
Laverack G, Health Promotion Practice: Building Empowered Communities (Open University Press 2007) <https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,shib&db=nlebk&AN=234222&site=ehost-live&scope=site&custid=s8454451>
Macdowall W, Bonell C and Davies M, Health Promotion Practice, vol Understanding public health (Open University Press 2006)
Maher AR, ‘Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in AdultsA Systematic Review and Meta-Analysis’ (2011) 306 JAMA: The Journal of the American Medical Association
——, ‘Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in Adults’ (2011) 306 JAMA
‘Map of Medicine | Home’ <http://www.mapofmedicine.com/>
Martinón-Torres G, Fioravanti M and Grimley Evans J, ‘Trazodone for Agitation in Dementia’ [2004] Cochrane Database of Systematic Reviews
‘Medicines Information - Evidence Search - Search Engine for Evidence in Health and Social Care’ <https://www.evidence.nhs.uk/>
‘Medicines Use Review and Prescription Intervention Service’ <http://psnc.org.uk/wp-content/uploads/2013/06/MUR-service-spec-Aug-2013-changes_FINAL.pdf>
Miller WR and Rollnick S, Motivational Interviewing: Helping People Change, vol Applications of motivational interviewing (3rd ed, Guilford Press 2013)
‘National Institute for Health and Care Excellence’ <http://www.nice.org.uk/>
‘NHS Health Check - NHS Choices’ <http://www.nhs.uk/Conditions/nhs-health-check/Pages/NHS-Health-Check.aspx>
‘NICE Clinical Knowledge Summaries (CKS)’ <http://cks.nice.org.uk/>
‘NPC | National Prescribing Centre’ <https://www.guidelinesinpractice.co.uk>
‘——’ <https://www.guidelinesinpractice.co.uk>
‘Optimising Treatment and Care for Behavioural and Psychological Symptoms of Dementia: A Best Practice Guide’ <https://www.alzheimers.org.uk/bpsdguide>
Pierre N. Tariot, M.D.; Rosemary Erb, R.N., B.S.N.; Carol Ann Podgorski, Ph.D.; Christopher Cox, Ph.D.; Shirish Patel, M.D.; Laura Jakimovich, M.S., R.N.; Carrie Irvine, B.A., ‘Efficacy and Tolerability of Carbamazepine for Agitation and Aggression in Dementia’ (1998) 155 PsychiatryOnline | American Journal of Psychiatry | Efficacy and Tolerability of Carbamazepine for Agitation and Aggression in Dementia 54
Prochaska JO, Norcross JC and DiClemente CC, Changing for Good (William Morrow 1994)
‘Reminyl Tablets - Summary of Product Characteristics (SPC) - (eMC)’
‘Risperdal Tablets, Liquid & Quicklet - Summary of Product Characteristics (SPC) - (eMC)’ <http://www.medicines.org.uk/emc/document.aspx?documentid=12818&docType=SPC>
Rollnick S, Mason P and Butler C, Health Behavior Change: A Guide for Practitioners (Churchill Livingstone 1999)
Rollnick S, Miller WR and Butler C, Motivational Interviewing in Health Care: Helping Patients Change Behavior, vol Applications of motivational interviewing (Guilford Press 2008)
‘Royal Pharmaceutical Society (RPS)’ <http://www.rpharms.com/home/home.asp>
‘Scottish Intercollegiate Guidelines Network (SIGN)’ <http://www.sign.ac.uk/>
‘Service Specification - New Medicine Service (NMS)’ <http://psnc.org.uk/wp-content/uploads/2013/06/NMS-service-spec-Aug-2013-changes_FINAL.pdf>
Sube Banerjee, ‘The Use of Antipsychotic Medication for People with Dementia: Time for Action. A Report for the Minister of State for Care Services’ <http://psychrights.org/research/digest/nlps/BanerjeeReportOnGeriatricNeurolepticUse.pdf>
‘TA217 Alzheimer’s Disease - Donepezil, Galantamine, Rivastigmine and Memantine: Guidance (MS Word Format)’ <http://guidance.nice.org.uk/TA217/Guidance/doc/English>
‘Treatment Protocol by NHS Medway: Treatment of Behaviour That Challenges’ <http://www.kmpt.nhs.uk/policies>
Waldemar G and others, ‘Tolerability of Switching from Donepezil to Memantine Treatment in Patients with Moderate to Severe Alzheimer’s Disease’ (2008) 23 International Journal of Geriatric Psychiatry 979
Walker R and Whittlesea C, Clinical Pharmacy and Therapeutics (5th ed, Churchill Livingstone 2012) <https://www.vlebooks.com/Product/Index/173020?page=0&startBookmarkId=-1>
Warner J and Smith T, ‘The Rise and Fall of Antipsychotic Prescribing in Dementia. Where Do We Go from Here?’ 14 The rise and fall of antipsychotic prescribing in dementia 24
